• Publications
  • Influence
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first‐line somatostatin analogue therapy have limited therapeutic options. This randomized,Expand
  • 781
  • 65
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
The need for standards in the management of patients with endocrine tumors of the digestive system prompted the European Neuroendocrine Tumor Society (ENETS) to organize a first Consensus Conference,Expand
  • 1,254
  • 62
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinicalExpand
  • 664
  • 25
Recommendations for management of patients with neuroendocrine liver metastases.
Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional andExpand
  • 280
  • 19
The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum
Well-differentiated neuroendocrine tumors (NETs) of the jejunum, ileum, and appendix are also collectively known as midgut carcinoids. Similar to NETs in general, the diagnosed incidence of theExpand
  • 319
  • 17
Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
We intended to identify the prognostic factors and the results of interventions on patients with liver metastatic midgut carcinoids. Five institutions that are part of United Kingdom and IrelandExpand
  • 201
  • 15
The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy
111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear medicine imaging modality of choice for identifying neuroendocrine tumors. However, there are cohortsExpand
  • 244
  • 12
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG
The aim was to assess the relevant distribution of the novel PET tracer 68Ga‐DOTATATE in neuroendocrine tumors (NETs) with combined positron emission tomography / computed tomography (PET/CT) andExpand
  • 333
  • 11
ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Colorectal Neuroendocrine Neoplasms
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms : colorectal neuroendocrine neoplasms
  • 176
  • 11
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
The diagnosed incidence of small intestine neuroendocrine tumors (SI-NETs) is increasing, and the underlying genomic mechanisms have not yet been defined. Using exome- and genome-sequence analysis ofExpand
  • 195
  • 11